Nadyeschka Rivera
Endocrinology, Diabetes & Metabolism · Rio Grande, PRNPI 1205284114
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,450 of the $7,791 with a category attached, or 82.8%. It is spread thinly across 21 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,245 and has fallen 93.0% since, to $156 in 2025.
Across 230 payments — averaging $33.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Boehringer Ingelheim$1K
- AstraZeneca$1K
- Sanofi-aventis U.S. LLC$567
- Novo Nordisk$506
- Bayer$478
- plus $2K from 15 others
What the payments were for
- Travel & lodging$1,34117%
- Food & beverage$6,45083%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 18 | $1,604 |
| Boehringer Ingelheim | 38 | $1,402 |
| AstraZeneca | 38 | $1,114 |
| Sanofi-aventis U.S. LLC | 27 | $567 |
| Novo Nordisk | 26 | $506 |
| Bayer | 6 | $478 |
| Amgen(2 entities) | 5 | $406 |
| Eli Lilly Export S.A. Puerto Rico Branch | 16 | $320 |
| Abbott | 15 | $252 |
| PBG Puerto Rico LLC | 10 | $185 |
| Dexcom, Inc. | 7 | $145 |
| Johnson & Johnson | 7 | $140 |
| Merck | 8 | $133 |
| Corcept Therapeutics | 1 | $125 |
| AbbVie | 1 | $120 |
| Lilly USA, LLC | 1 | $119 |
| Rhythm Pharmaceuticals, Inc. | 1 | $70 |
| Radius Health, Inc. | 2 | $33 |
| Novartis | 1 | $29 |
| Insulet Corporation | 1 | $23 |
| Pfizer Pharmaceuticals LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,791 in reported general payments places this provider in the 70th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 384 | $402,771 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 312 | $204,089 |
| OzempicSemaglutide | 149 | $149,594 |
| JardianceEmpagliflozin | 170 | $117,345 |
| GlyxambiEmpagliflozin/Linagliptin | 122 | $91,016 |
| TradjentaLinagliptin | 148 | $83,475 |
| FarxigaDapagliflozin Propanediol | 76 | $61,251 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 97 | $61,068 |
| Jentadueto XrLinagliptin/Metformin Hcl | 99 | $59,754 |
| MounjaroTirzepatide | 55 | $58,729 |
| Xigduo XrDapaglifloz Propaned/Metformin | 96 | $58,169 |
| SynthroidLevothyroxine Sodium | 617 | $36,110 |
| LantusInsulin Glargine,hum.Rec.Anlog | 267 | $27,503 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 192 | $19,023 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 31 | $19,011 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTrijardy Xr, Jardiance, Glyxambi, Tradjenta, Synjardy Xr | $1,402 | $616,748948 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30, Humulin N | $119 | $472,133537 claims |
| Novo NordiskOzempic | $506 | $149,594149 claims |
| AstraZenecaFarxiga | $1,114 | $61,25176 claims |
| AbbVieSynthroid | $120 | $36,110617 claims |
| Sanofi-aventis U.S. LLCLantus | $567 | $27,503267 claims |
| MerckJanumet Xr | $133 | $19,01131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in Rio Grande
- Jose Garcia MateoPonce$945K
- Manuel Alegre-HernandezSan Juan$156K
- Monica Ortiz-RiveraSan Juan$148K
- Alex Gonzalez BossoloSan Juan$110K
- Michelle Mangual GarciaSan Juan$87K
- Meliza Martinez RodriguezSan Juan$80K
- Milliette Alvarado SantiagoRio Piedras$75K
- Altagracia Alcantara GonzalezBayamon$58K
- Jean Pujals KuryBayamon$50K
- Rafael GonzalezRio Piedras$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.